United States

Press Releases

08/08/2018
Seqirus Begins Shipping 2018-2019 Influenza Vaccines to the U.S. Market

Seqirus announced today it has begun shipping its portfolio of seasonal influenza vaccines to customers in the United States for the 2018-2019 influenza season. Seqirus, one of the largest influenza vaccine companies in the world, and a leading innovator of new technologies, expects to distribute over 50 million doses to the U.S. market this year.

More.

07/02/2018
Seqirus Joining UIVI to Advance Universal Flu Vaccine Research
Human Vaccines Project and Seqirus Partner to advance Universal Flu Vaccine research. More.

04/18/2018
New PNG Snakebite Project to Improve Access to Antivenoms
A new partnership to help save the lives of people bitten by venomous snakes was launched today in Port Moresby. The ‘PNG Snakebite Partnership’ is a three-year project involving the National Department of Health, the Australian Government, Seqirus Pty Ltd, and the Charles Campbell Toxinology Centre, at the University of Papua New Guinea (UPNG). More.

03/13/2018
Seqirus answers the call for better and faster influenza vaccine technologies
Seqirus, a leading innovator in influenza vaccines and pandemic preparedness, today welcomed calls from US Health Officials for greater efforts to be made to develop better and faster influenza vaccine technologies. The comments were made at a hearing conducted by the Energy and Commerce Subcommittee on Oversight and Investigations examining preparedness and response to seasonal influenza on Thursday 8 March 2018.1 More.

12/04/2017
Be FLUent Partnership Shines Spotlight on Importance of Flu Prevention in Seniors
Seqirus today, in partnership with leading health care provider advocacy organizations, announced the launch of Be FLUent, a collaborative initiative that brings together nurse practitioners, physician assistants and pharmacists to drive dialogue about influenza (flu) prevention between health care providers and their patients age 65 and older. More.

09/14/2017
Seqirus Receives FDA Approval of AFLURIA QUADRIVALENT® (Influenza Vaccine) for People Five Years of Age and Older in the U.S.
Seqirus announced today that the US Food and Drug Administration (FDA) has approved AFLURIA QUADRIVALENT (Influenza Vaccine) for use in individuals five years of age and older, extending the company’s broad portfolio of influenza vaccine offerings. AFLURIA QUADRIVALENT, which was first approved in the U.S. on August 2016 for individuals 18 and older, helps protect against two influenza A strain viruses and two B strain viruses.3,10 More.

09/12/2017
Seqirus Donates Influenza Vaccine for Hurricane Harvey Relief in Texas
As hurricane recovery efforts continue in Texas, the U.S. Department of Health and Human Services (DHHS), has requested urgent support to help displaced residents fight the onset of influenza. More.

08/07/2017
Seqirus announces major advances in pandemic preparedness
Seqirus, a global leader in the prevention of influenza, announced today that the accelerated development of cell-based manufacturing technology at its state-of-the-art manufacturing facility in Holly Springs, North Carolina, has delivered a four-fold increase in seasonal influenza vaccine output in just two years, strengthening the United States’ capacity to respond to pandemic threats. More.

07/20/2017
Seqirus Begins Shipping 2017-2018 Influenza Vaccines to the U.S. Market
Seqirus announced today it has begun shipping its portfolio of seasonal influenza vaccines to customers in the United States for the 2017-2018 influenza season. More.

06/21/2017
Seqirus announces next major advancement in cell-based influenza vaccine technology
Seqirus, a leading innovator in influenza vaccines and pandemic preparedness, today announced the next major advancement in the use of cell-based technology at the state-of-the art manufacturing facility in Holly Springs, North Carolina. More.

07/11/2016
Seqirus is first-to-market with shipment of seasonal influenza vaccines to the US for the 2016-2017 season
Seqirus announced today that it has begun shipment of its portfolio of influenza vaccines to customers in the US market for the 2016-2017 season. More.

The information presented on this site is intended for US residents only.
© 2018 Seqirus All rights reserved.
Seqirus is a trademark of CSL Limited.

BCSL14-02-0003 06/2014